Please use this identifier to cite or link to this item:
|Title:||Inhibition of human enhancer of zeste homolog 2 with tambjamine analogs|
Soto Cerrato, Vanessa
Orozco López, Modesto
Pérez Tomás, Ricardo E.
Tractament adjuvant del càncer
Adjuvant treatment of cancer
|Publisher:||American Chemical Society|
|Abstract:||Combining computational modeling, de novo compound synthesis, and in vitro and cellular assays, we have performed an inhibition study against the enhancer of zeste homolog 2 (EZH2) histone-lysine N-methyltransferase. This enzyme is an important catalytic component of the PRC2 complex whose alterations have been associated with different cancers. We introduce here several tambjamine-inspired derivatives with low micromolar in vitro activity that produce a significant decrease in histone 3 trimethylation levels in cancer cells. We demonstrate binding at the methyl transfer active site, showing, in addition, that the EZH2 isolated crystal structure is capable of being used in molecular screening studies. Altogether, this work provides a successful molecular model that will help in the identification of new specific EZH2 inhibitors and identify a novel class of tambjamine-derived EZH2 inhibitors with promising activities for their use in cancer treatment.|
|Note:||Versió postprint del document publicat a: https://doi.org/10.1021/acs.jcim.7b00178|
|It is part of:||Journal of Chemical Information and Modeling, 2018, vol. 57, num. 8, p. 2089-2098|
|Appears in Collections:||Articles publicats en revistes (Patologia i Terapèutica Experimental)|
Articles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))
Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.